Skip Navigation


Annals of Oncology Advance Access originally published online on June 9, 2005
Annals of Oncology 2005 16(7):997-998; doi:10.1093/annonc/mdi231
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/997    most recent
mdi231v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Besse, B.
Right arrow Articles by Le Chevalier, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Besse, B.
Right arrow Articles by Le Chevalier, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Editorial

Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy

B. Besse1, J. C. Soria1 and T. Le Chevalier1,2,*

1 Institut Gustave Roussy, Villejuif, France2 Institut National du Cancer, Paris, France

* Email: tle-che@igr.fr

The first 10% of the full text of this article appears below.

A doublet chemotherapy, generally cisplatin or carboplatin-based, is the standard of care in the management of advanced non-small cell lung cancer (NSCLC) patients, defined as unresectable stage IIIB or stage IV disease [1Go]. Numerous trials have established the superiority of third generation cytotoxic agent combinations over old fashion regimens (2–4). In one of these studies published by Bonomi et al., the classical etoposide-cisplatin doublet (EC, etoposide 100 mg/m2 days 1 to 3, plus cisplatin 75 mg/m2 day 1) was compared with two different paclitaxel-cisplatin regimens (cisplatin 75 mg/m2 plus paclitaxel 135 or 250 mg/m2 as . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'Brien, D. Dunlop, K. O'Byrne, V. Laurence, et al.
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
Ann. Onc., July 1, 2006; 17(7): 1111 - 1119.
[Abstract] [Full Text] [PDF]